PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Q2 2025 Earnings | 08/07/2025

About this video

PROCEPT BioRobotics reported strong financial results for the second quarter of 2025, with total revenue reaching $79.2 million, marking a 48% year-over-year increase. This growth was driven by robust demand, especially in the U.S. market where handpiece and consumable revenue surged 58% to $43.1 million. U.S. system and rental revenue rose 24% to $22.1 million, while international revenue grew 69% to $9.6 million, reflecting successful expansion efforts. Despite increased revenue, the company posted a net loss of $19.6 million, an improvement from the $25.6 million loss in the same quarter last year. Adjusted EBITDA loss narrowed substantially to $8.0 million from $17.9 million a year ago. Gross margin improved significantly to 65% from 59%, aided by enhanced operational efficiencies and higher selling prices in the U.S. robotic systems segment. Operational highlights included selling 51 robotic systems in the U.S., expanding the installed base to 595 systems. The company focused on advancing utilization of its Aquablation® therapy within the U.S. benign prostatic hyperplasia (BPH) hospital market and increasing commercial efforts internationally. Clinical research also progressed with accelerated enrollment in the WATER IV prostate cancer study. PROCEPT BioRobotics raised its full-year 2025 revenue guidance to $325.5 million, representing 45% growth over 2024. The company projects full-year gross margin around 64.5%, operating expenses near $302 million, and an adjusted EBITDA loss of about $35 million as it continues to invest in growth initiatives. A leadership transition was announced with Larry Wood appointed as CEO, effective September 2, 2025, bringing four decades of medical technology experience. Management highlighted persistent macroeconomic challenges and investment-driven losses, but emphasized strong momentum in system sales, consumables, and international markets positioning the company well for sustained growth. About Inside Ticker: Inside Ticker delivers timely, in-depth financial news and earnings analysis to empower investors with actionable insights on global companies across sectors. For comprehensive video analysis and real-time updates, visit https://www.insideticker.com/. #PROCEPTBioRobotics #PRCT #Q22025 #Earnings #FinancialResults #RevenueGrowth #NetLoss #EPS #AdjustedEBITDA #RoboticSurgery #SurgicalRobotics #AquablationTherapy #BPH #Urology #MedicalDevices #HealthcareInnovation #GrossMarginImprovement #InternationalExpansion #SystemSales #Consumables #WATERIVStudy #ClinicalResearch #LeadershipChange #LarryWood #MedicalTechnology #InvestorUpdates #MarketExpansion #OperationalEfficiency #NASDAQ #TechEarnings #InsideTicker #GrowthStrategy #MedicalRobotics #SurgicalInnovation #Biotech #PatientCare